Integrity Guard Active. Quantitative claims for finerenone are restricted to Phase 1b pending final production-backtest verification. This site maintains a frozen posture for all numeric evidence until the high-integrity gate is cleared. See Validation.
Lane note
Finerenone / albuminuric CKD
Threshold transfer statement only; exact lead-time and holdout claims are frozen pending active production audit.
- Named state
- Active Audit
- Observation
- The hardening read is under re-verification in a time-correct replay of the public record.
- Limits
- This is a measurement, not a prediction. The evidence chain of custody shows what was publicly observable at the time; the stress test measures resistance to change, not truth.
Read the lane note →
What this page does not say
- Drug name, condition, institution, and review date are not published. They are disclosed only inside a private brief.
- Additional lanes are under observation. Entity names and build status are disclosed in private briefs only.
- Numeric claims are not currently published. Future numeric claims must carry lineage suffixes linking to the specific measurement artifact.
- A hardened claim can still be wrong. Hardening measures institutional resistance to change, not truth.
Action
Request a private brief for one live review window.
Send the disputed claim with a real review date. We reply with fit, limits, and next steps within one business day.
